New York, June 27, 2026, 10:08 EDT
- ImmunityBio finished Friday at $8.71, jumping 11.8% with around 41.2 million shares traded.
- About 46% of the stock’s trading volume for the past five sessions came on Friday.
- A director plans to sell 25,000 shares, a filing from June 26 said. That’s roughly 0.06% of Friday’s trading volume.
- Traders are watching Monday’s open to see if demand from the Russell reconstitution sticks.
ImmunityBio, Inc. NASDAQ:IBRX goes into the week with a cleaner tape test despite what the price action shows. Shares were up 11.8% Friday, closing at $8.71. Trading volume topped 41.2 million shares, triple Google Finance’s average of 13.39 million. Market cap was close to $9.1 billion.
Volume concentration was heavy, with Friday making up roughly 46% of ImmunityBio’s total five-day volume on the tape. The stock is up about 18% since closing at $7.36 on June 18.
The stock is now at a level where index flow can play a big role. FTSE Russell said its June 2026 reconstitution was effective after the U.S. close on June 26, with changes to membership starting from the open on Monday, June 29. The final summary shows the large-cap/small-cap split at around $5.7 billion.
ImmunityBio traded around 60% above the threshold on Friday, but Russell inclusion relies on official rank-day numbers, not just a late-week price. FTSE Russell said 61 names joined the Russell 1000, including 42 up from the Russell 2000. Six of those new Russell 1000 companies are health care stocks.
Technology and Industrials were out ahead in the shift into the Russell 1000, FTSE Russell’s director of product management Catherine Yoshimoto said in May as the firm posted early reconstitution numbers.
The trade is in focus because Monday splits off rebalance flows from wider demand. If volume drops back to normal, Friday’s jump could be about index closing. If it stays high, there’s more support for the rally. As of Saturday, ImmunityBio’s investor-relations page showed no new events.
ImmunityBio, Inc. director Barry J. Simon sold 25,000 shares on June 24 at a weighted average of $7.8763 per share, according to a June 26 Form 4. The sale was under a Rule 10b5-1 plan put in place on Dec. 18, 2025. After the trade, Simon held 2,802,788 shares. There were no clinical or commercial updates reported in the past one to two days.
The sale totaled $196,908, less than 1% of Simon’s reported post-sale stake and about 0.06% of the stock’s volume on Friday. That’s not enough to move the tape. Investors got a new insider-liquidity read just as the stock traded near Russell cutoff levels this week.
Anktiva is still key to the story here. ImmunityBio posted first-quarter net product revenue of about $44.2 million, jumping 168% from last year. Cash and marketable securities totaled roughly $381 million. CEO Richard Adcock said the company remains “focused on scaling in the U.S. and expanding across an increasing number of global markets.” SEC
ImmunityBio (ImmunityBio, Inc.)’s next major regulatory decision is a long way out. The FDA has accepted the company’s supplemental biologics license application for Anktiva plus BCG in BCG-unresponsive non-muscle invasive bladder cancer with papillary disease, setting the PDUFA deadline for Jan. 6, 2027. Founder and executive chairman Patrick Soon-Shiong said patients with this kind of bladder cancer are often left with “the option of a total radical cystectomy” and said the company plans to keep working with the agency through the review.
Risk is still a factor here. In March, the FDA said some marketing around Anktiva was misleading, warning that the data doesn’t back up claims the drug works for all cancers or can stop cancer. Regulators reiterated the approved use: Anktiva plus BCG is cleared only for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
Russell changes take effect Monday, so traders will watch the first volume print closely. Another question this week is if ImmunityBio stays near Friday’s $8.71 close, with no company events on the calendar.
